Adocia’s Double-Hormone Diabetes Treatment is Set to Enter Phase I Trial

Adocia, a French biotech, will initiate a Phase I clinical study to test a diabetes treatment that maximizes the effect of two blood sugar-lowering hormones.

Adocia will start a Phase I clinical trial to test the safety and tolerability of its BioChaperone Pramlintide Insulin treatment to control blood sugar levels after a meal in type 1 diabetes patients. Adocia expects its technology could help patients keep their blood sugar levels under control after a meal using a combination of two hormones, insulin and pramlintide.

Leave a Reply

Your email address will not be published. Required fields are marked *